Cantor Fitzgerald’s Moderna MRNA Stock Holding History

Cantor Fitzgerald’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.59M	Buy	22,772 +12,763	+128%	+$660K	0.02%	208
2026 Q1	$508K	Buy	+10,009	New	+$467K	0.01%	216
2025 Q4	–	Sell	-59,284	Closed	-$1.53M	–	309
2025 Q3	$1.53M	Sell	59,284 -306	-0.5%	-$8.54K	0.01%	177
2025 Q2	$1.64M	Sell	59,590 -34,546	-37%	-$910K	0.03%	120
2025 Q1	$2.67M	Buy	94,136 +77,175	+455%	+$2.74M	0.06%	70
2024 Q4	$705K	Buy	+16,961	New	+$811K	0.01%	101
2024 Q3	–	Sell	-25,000	Closed	-$2.97M	–	270
2024 Q2	$2.97M	Buy	+25,000	New	+$3.16M	0.58%	39
2024 Q1	–	Sell	-200	Closed	-$498K	–	307
2023 Q4	$498K	Buy	+200	New	+$16.8K	0.1%	100
2023 Q2	–	Sell	-4,840	Closed	-$743K	–	618
2023 Q1	$743K	Sell	4,840 -3,215	-40%	-$530K	0.02%	399
2022 Q4	$1.45M	Sell	8,055 -20,765	-72%	-$3.4M	0.03%	355
2022 Q3	$3.41M	Sell	28,820 -1,532	-5%	-$232K	0.07%	279
2022 Q2	$4.34M	Buy	+30,352	New	+$4.34M	0.08%	262

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Cantor Fitzgerald's MRNA Position: Q2 2026 in Review

Cantor Fitzgerald increased its Moderna (MRNA) stake by 128% in Q2 2026, buying an estimated $660K and bringing the position to 22,772 shares worth $1.59M. The position accounts for 0.02% of the portfolio, ranked #208.

Cantor Fitzgerald first reported a position in MRNA in Q2 2022 and has held it in 12 quarters since. The position peaked at $4.34M in Q2 2022. 780 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

Cantor Fitzgerald held 22,772 shares of Moderna worth $1.59M as of Q2 2026.
Cantor Fitzgerald bought 12,763 Moderna shares in Q2 2026, an estimated $660K.
Moderna made up 0.02% of Cantor Fitzgerald's portfolio in Q2 2026, its #208 holding.
Cantor Fitzgerald first reported a position in Moderna in Q2 2022 and has held it in 12 quarters since.
Cantor Fitzgerald's Moderna position peaked at $4.34M in Q2 2022.
780 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Cantor Fitzgerald's 13F filing for Q2 2026, filed 14 Aug 2026.